• 1
    Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958; 46: 218-223.
  • 2
    Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris N, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008: 262-264.
  • 3
    Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc. 1969; 1: 106-112.
  • 4
    Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008: 343-350.
  • 5
    Oertel SH, Verschuuren E, Reinke P, et al. Effect of Anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant. 2005; 5: 2901-2906.
  • 6
    Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood. 2006; 107: 3053-3057.
  • 7
    Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13:196206.
  • 8
    Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964; 1: 702-703.
  • 9
    Klein E, Kis LL, Klein G. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene. 2007; 26: 1297-1305.
  • 10
    Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol. 2010; 149: 484-497.
  • 11
    Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010; 28: 3360-3365.
  • 12
    Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematol Am Soc Hematol Educ Program. 2008: 341-348.
  • 13
    Hoffmann C, Wolf E, Wyen C, et al. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma. 2006; 47: 1872-1880.
  • 14
    Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008; 113: 117-125.
  • 15
    Kelly JL, Toothaker SR, Ciminello L, et al. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma. 2009; 9: 307-310.
  • 16
    Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011; 22: 1859-1864.
  • 17
    Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106: 1569-1580.
  • 18
    Choquet S, Trappe R, Leblond V, et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica. 2007; 92: 273-274.
  • 19
    Xicoy B, Ribera J-M, Esteve J, et al. Post-transplant Burkitt's leukemia or lymphoma. Study of 5 cases treated with specific intensive therapy (PETHEMA ALL-3/97 trial). Leuk Lymphoma. 2003; 44: 1541-1543.
  • 20
    Gong JZ, Stenzel TT, Bennett ER, et al. Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of 5 cases. Am J Surg Pathol. 2003; 27: 818-827.
  • 21
    Picarsic J, Jaffe R, Mazariegos G, et al. Post-transplant Burkitt lymphoma is a more aggressive and distinct form of post-transplant lymphoproliferative disorder. Cancer. 2011; 117: 4540-4550.
  • 22
    Trappe R, Choquet S, Oertel SHK, et al. Sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD—moving forward to a first standard of care: results from a prospective international multicenter trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 100.
  • 23
    Oertel SH, Papp-Vary M, Anagnostopoulos I, et al. Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol. 2003; 123: 830-835.
  • 24
    Trappe R, Zimmermann H, Fink S, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica. 2011; 96: 1067-1071.
  • 25
    Zimmermann H, Oschlies I, Fink S, et al. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry [published online ahead of print January 9, 2012]. Transplantation. 2012.
  • 26
    Ziegler JL, Bluming AZ, Fass L, Morrow RH. Relapse patterns in Burkitt's lymphoma. Cancer Res. 1972; 32: 1267-1272.
  • 27
    Smeland S, Blystad AK, Kvaloy SO, et al. Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of 3 successive regimens. Ann Oncol. 2004; 15: 1072-1078.
  • 28
    Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol. 1986; 4: 847-858.
  • 29
    Dunleavy K, Pittaluga S, Janik J, et al. Novel Treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: preliminary results showing excellent outcome [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108. Abstract 2736.
  • 30
    Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002; 99: 2685-2693.
  • 31
    Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant. 2011; 11: 336-347.